Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 1.21% is 56% below its 5-year average of 2.77%, near the low end of its 5-year range (0.00%–4.62%).
As of the fiscal period ended Tuesday, June 30, 2026. 56.53% below its 12-month average of 2.79%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.21%.
DEBT TO ASSETS RATIO
1.21%
DEBT TO ASSETS RATIO AVG TTM
2.79%
DEBT TO ASSETS RATIO AVG 3Y
3.08%
DEBT TO ASSETS RATIO AVG 5Y
2.77%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-56.53%
CURRENT VS 3Y AVG
-60.65%
CURRENT VS 5Y AVG
-56.27%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+1246.42%
vs the sector median at left
Shattuck Labs, Inc.
Market Cap
$540.43M
Debt to Assets Ratio
1.21%
TTM Avg
2.79%
3Y Avg
3.08%
5Y Avg
2.77%
Market Cap
$542.44M
Debt to Assets Ratio
0.51%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$543.46M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$530.30M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$528.07M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$522.80M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$560.00M
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$560.59M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | $540.43M | 1.21% | 2.79% | 3.08% | 2.77% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $542.44M | 0.51% | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $543.46M | 0.00% | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $530.30M | 0.02% | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $529.60M | 0.01% | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $528.07M | 0.00% | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $522.80M | 0.00% | N/A | N/A | N/A |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $560.59M | 0.01% | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $517.30M | 0.07% | N/A | N/A | N/A |
Debt/Assets
1.2%
Debt/Equity
0.01
Current Ratio
27.59
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 1.21% |
| 2026-03-31 | 2.83% |
| 2025-12-31 | 2.66% |
| 2025-09-30 | 2.62% |
| 2025-06-30 | 4.62% |
| 2025-03-31 | 4.14% |
| 2024-12-31 | 3.74% |
| 2024-09-30 | 3.24% |
| 2024-06-30 | 2.97% |
| 2024-03-31 | 2.74% |
| 2023-12-31 | 2.63% |
| 2023-09-30 | 3.36% |
| 2023-06-30 | 2.94% |
| 2023-03-31 | 2.26% |
| 2022-12-31 | 2.39% |
| 2022-09-30 | 1.97% |
| 2022-06-30 | 1.82% |
| 2022-03-31 | 1.75% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2019-12-31 | 0.00% |
